Holen Sie sich die Stockscreener-App
241.76
2.61%
-6.48
Handel nachbörslich:
242.00
0.24
+0.10%
Schlusskurs vom Vortag:
$248.24
Offen:
$250.11
24-Stunden-Volumen:
499.62K
Relative Volume:
0.89
Marktkapitalisierung:
$6.75B
Einnahmen:
$7.46M
Nettoeinkommen (Verlust:
$-326.53M
KGV:
-18.07
EPS:
-13.3803
Netto-Cashflow:
$-282.53M
1W Leistung:
-6.97%
1M Leistung:
-21.76%
6M Leistung:
-24.54%
1J Leistung:
+48.58%
1-Tages-Spanne:
$241.76
$251.78
1-Wochen-Bereich:
$236.79
$259.50
52-Wochen-Spanne:
$154.45
$392.70
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
241.76 | 6.75B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-15 | Eingeleitet | UBS | Buy |
| 2026-07-13 | Eingeleitet | Goldman | Buy |
| 2026-06-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-02 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis and Remagine partner to develop ulixacaltamide patch - scanx.trade
Praxis grants 951 RSUs to new employees under inducement plan - scanx.trade
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Fourteen new employees receive Praxis stock awards covering 3,478 shares. - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade) - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Sixty-six new employees receive stock awards from Praxis. They vest over four years. - Stock Titan
Praxis Precision Medicines (PRAX) Climbs 1.23% as Shares Press Toward $375.69 ResistanceRounding Top - careplusvn.com
PRAX Stock Price, Quote & News - Syfe
S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead - Barron's
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - Yahoo Finance
Breakeven On The Horizon For Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Moomoo
PRAX Maintains by Goldman Sachs -- Price Target Raised to $575 - GuruFocus
Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally - Quiver Quantitative
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $575 - Moomoo
Praxis (PRAX) Update: Climbs 1.92% to $376.94 for the Current Session; the Supplied Trading Band Runs From $358.09 to $395.79Percent Below MA - vinanet.vn
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Nigeria
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Canada
Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says - marketscreener.com
Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945 - Moomoo
Raymond James raises Praxis Precision Medicines price target on pipeline outlook By Investing.com - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com India
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com
Praxis Precision Medicines (PRAX) Holds Near $366.81 as Consolidation Tightens Between Key LevelsBlock Trade Flow - vinanet.vn
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan
(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportQuality Factor - dars.gov.et
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView
Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportWeak Sell Signals - vinanet.vn
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView
High Growth Tech Stocks in the US to Watch - simplywall.st
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DeSimone Jill | Director |
Jun 24 '26 |
Sale |
311.32 |
11,600 |
3,611,335 |
2,337 |
| DeSimone Jill | Director |
Jun 24 '26 |
Proposed Sale |
311.32 |
11,600 |
3,611,336 |
0 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Option Exercise |
73.76 |
25,130 |
1,853,531 |
45,962 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
| Nemiroff Alex | Officer |
Nov 20 '25 |
Proposed Sale |
193.09 |
25,130 |
4,852,249 |
0 |
| Mastrocola Lauren | Officer |
Nov 20 '25 |
Proposed Sale |
192.08 |
13,600 |
2,612,239 |
0 |
| MITCHELL DEAN J | Director |
Option Exercise |
39.51 |
12,251 |
483,991 |
17,251 |
2.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):